Lv4
500 积分 2021-05-30 加入
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
8天前
已完结
Correspondence - Tranexamic acid for traumatic brain injury
8天前
已关闭
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
9天前
已完结
Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial
9天前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
9天前
已完结
P0640 Development and characterization of LQ080, a novel extended half-life bispecific TL1A/IL-23 p19 single domain antibody for the treatment of IBD
12天前
已完结
TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease
1个月前
已完结
Advanced Combination Therapy in Inflammatory Bowel Disease: What Does the Future Hold?
1个月前
已完结
Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies
1个月前
已完结
Brighter days ahead: the shifting landscape of IBD therapy
1个月前
已完结
皖公网安备34019202002308
